Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. May’s top news stories
  2. Lack of CMO availability threatens cell and gene therapy development
  3. CD47-targeted therapies: the breast cancer mop?
  4. Through CRISPR gene editing we can change the nature of our species
  5. Could groundbreaking gene therapies offer a breakthrough to retinal disease sufferers?

Latest Content

June’s top news stories

Servier and Galapagos commenced the ROCCELLA Phase 2 clinical trial to evaluate the efficacy and safety of S201086/GLPG1972 to treat patients with knee osteoarthritis (OA); and Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company reported positive top-line results from the EASE trial programme. Drugdevelopment-technology.com wraps up the key news stories from June 2018.

Laser Microdissection with PALM MicroBeam Technology

Its laser microdissection with PALM MicroBeam technology allows for contact-free and uncontaminated specimen collection from specific compartments of skin and hair follicles for use in next-generation sequencing analysis.

May’s top news stories

Abivax unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory diseases; and Cancer Research UK and Experimental Cancer Medicine Centres (ECMC) Network joint venture (JV) Combinations Alliance started the SeluDex trial, a Phase I clinical study to evaluate selumetinib in combination with dexamethasone for treating leukaemia.

From Gene to Finished Vial

Biovian is a one-stop-shop in GMP contract manufacturing of biopharmaceuticals, covering services from early development to finished vial.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top